ImmunityBio (IBRX) Clinical Trial for Lymphona Drug Follows $505M Convertible Note Change

ImmunityBio Inc. (NASDAQ:IBRX) is one of the 13 hot stocks to buy with the highest upside potential. On February 2, ImmunityBio Inc. (NASDAQ:IBRX) announced that it has initiated a Phase 2 clinical trial evaluating a novel combination immunotherapy for patients with indolent B-cell non-Hodgkin lymphoma (iNHL). Meanwhile, on January 26, ImmunityBio Inc. (NASDAQ:IBRX) amended a $505 million convertible promissory note with Nant Capital LLC, allowing the noteholder to convert any portion of the outstanding p ...